Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNLX 
Genelux Corporation Common Stock (GNLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: GNLX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.33
1 Year Target Price $19.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.96% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 211.57M USD | Price to earnings Ratio - | 1Y Target Price 19.33 |
Price to earnings Ratio - | 1Y Target Price 19.33 | ||
Volume (30-day avg) 5 | Beta -0.1 | 52 Weeks Range 1.99 - 8.54 | Updated Date 11/30/2025 |
52 Weeks Range 1.99 - 8.54 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.88 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.22 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -64.27% | Return on Equity (TTM) -123.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 193276846 | Price to Sales(TTM) 12362.41 |
Enterprise Value 193276846 | Price to Sales(TTM) 12362.41 | ||
Enterprise Value to Revenue 6302.51 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 38051771 | Shares Floating 29446209 |
Shares Outstanding 38051771 | Shares Floating 29446209 | ||
Percent Insiders 13.15 | Percent Institutions 30.7 |
Upturn AI SWOT
Genelux Corporation Common Stock
Company Overview
History and Background
Genelux Corporation was founded in 2005 with a focus on developing innovative cancer therapies using oncolytic viruses. Initially a research-driven organization, it has evolved into a clinical-stage biopharmaceutical company.
Core Business Areas
- Oncolytic Virus Immunotherapy: Developing and commercializing oncolytic viruses for the treatment of various cancers.
- GL-ONC1: Genelux's lead product candidate, an oncolytic vaccinia virus designed to selectively target and destroy cancer cells while stimulating an immune response.
Leadership and Structure
The leadership team consists of experienced executives in biopharmaceuticals and oncology. The organizational structure is typical of a biotech company, with departments focused on research, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- GL-ONC1: GL-ONC1 is Genelux's lead oncolytic virus immunotherapy candidate, currently in clinical trials for ovarian cancer and other solid tumors. The market share is currently negligible as the product is not yet approved. Competitors include companies developing other oncolytic viruses such as Amgen (T-VEC), Replimune (RP1), and Oncolytics Biotech (pelareorep).
Market Dynamics
Industry Overview
The oncolytic virus immunotherapy market is a rapidly growing segment within oncology, driven by the potential to provide targeted cancer therapy with fewer side effects compared to traditional treatments. The market is competitive with increasing investment and clinical trials.
Positioning
Genelux is positioned as a clinical-stage company focused on developing GL-ONC1 as a novel oncolytic immunotherapy. Their competitive advantage lies in the unique properties of their virus and its potential for broad application across multiple cancer types.
Total Addressable Market (TAM)
The global oncolytic virus therapy market is projected to reach billions of dollars. Genelux's success depends on clinical trial outcomes and regulatory approvals, positioning them to capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virus platform
- Promising preclinical and clinical data
- Experienced management team
- Targeted cancer therapy approach
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
- Product not yet approved for commercial use
Opportunities
- Expansion into new cancer indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Advancements in oncolytic virus technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cancer therapies
- Financial market volatility
Competitors and Market Share
Key Competitors
- AMGN
- RPIM
- ONCY
Competitive Landscape
Genelux faces competition from larger pharmaceutical companies with established cancer therapies. Their advantage lies in the potential of GL-ONC1 as a novel oncolytic virus immunotherapy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited to preclinical and clinical development activities.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and commercialization of GL-ONC1. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing GL-ONC1 through clinical trials, exploring new indications for the virus, and seeking strategic partnerships.
Summary
Genelux Corporation is a clinical-stage biopharmaceutical company with potential in the oncolytic virus immunotherapy market. Its future depends heavily on the success of its lead product candidate, GL-ONC1, in clinical trials. The company needs to secure funding and partnerships to navigate the competitive landscape. Clinical trial failures and regulatory hurdles pose significant risks, while successful commercialization would drive significant growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Genelux Corporation website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information provided is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas D. Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.genelux.com |
Full time employees 24 | Website https://www.genelux.com | ||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.